Viagra Connect hits UK shelves
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Pfizer is preparing a wide-ranging consumer marketing campaign to support the launch of its Viagra Connect (50mg sildenafil) product in the UK, after the country’s first OTC medicine for erectile dysfunction hit the shelves yesterday.
You may also be interested in...
Pfizer Building Viagra As Pan-European Consumer Health Brand With Rx-To-OTC Switch In Norway
Pfizer has taken the first steps towards turning its Viagra erectile dysfunction treatment into a pan-European OTC brand by taking advantage of Norway's new "non-prescription medicines with guidance" category to secure the Rx-to-OTC switch of the product. Norway will be the second European market where Viagra is available OTC after the UK switched the drug in 2017.
Thinking About Switching? Dr Gauld On The Go-To Markets Today
In this first installment of an exclusive three-part series, global switch expert Dr Natalie Gauld speaks to HBW Insight about what makes a country an attractive environment for switching and highlights those markets leading the way today.
China Approves World’s First Bispecific IO Drug Amid PD-1/L1 Glut
Akeso’s PD-1/CTLA-4-targeting therapy cadonilimab has been the front-runner in the bispecific antibody field in China, leading about 50 other similar agents under development by domestic pharma firms. With a new conditional approval, it has also gained a head start over home-grown PD-1/L1 antibody rivals in the cervical cancer space.